Michael J. Asmus

483 total citations
26 papers, 319 citations indexed

About

Michael J. Asmus is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Michael J. Asmus has authored 26 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Physiology, 16 papers in Pulmonary and Respiratory Medicine and 4 papers in Pharmacology. Recurrent topics in Michael J. Asmus's work include Asthma and respiratory diseases (16 papers), Inhalation and Respiratory Drug Delivery (11 papers) and Respiratory and Cough-Related Research (6 papers). Michael J. Asmus is often cited by papers focused on Asthma and respiratory diseases (16 papers), Inhalation and Respiratory Drug Delivery (11 papers) and Respiratory and Cough-Related Research (6 papers). Michael J. Asmus collaborates with scholars based in United States, South Africa and Canada. Michael J. Asmus's co-authors include Leslie Hendeles, Sarah E. Chesrown, James M. Sherman, Günther Hochhaus, Heather J. Zar, Eugene Weinberg, Gary Stevens, Robert J. Sanchez, Cynthia Huffman and L. Pauer and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Michael J. Asmus

25 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael J. Asmus United States 12 182 172 38 30 26 26 319
Thomas F. Morley United States 9 182 1.0× 53 0.3× 18 0.5× 13 0.4× 10 0.4× 17 311
C. Maiolo Italy 11 179 1.0× 234 1.4× 7 0.2× 74 2.5× 14 0.5× 22 462
M.L. Diament United Kingdom 11 235 1.3× 125 0.7× 14 0.4× 14 0.5× 17 0.7× 29 420
J.M. Daly United States 8 73 0.4× 105 0.6× 3 0.1× 17 0.6× 33 1.3× 29 314
S. Lal United Kingdom 10 167 0.9× 143 0.8× 18 0.5× 14 0.5× 21 0.8× 19 314
G.P. McLoughlin United Kingdom 8 85 0.5× 129 0.8× 20 0.5× 11 0.4× 19 0.7× 12 481
E. S. Snell United States 10 47 0.3× 122 0.7× 14 0.4× 9 0.3× 23 0.9× 22 458
David J. Cangemi United States 12 62 0.3× 73 0.4× 12 0.3× 5 0.2× 14 0.5× 43 477
Kumar Ashutosh United States 12 338 1.9× 100 0.6× 15 0.4× 17 0.6× 6 0.2× 19 426
Daniel M. Baer United States 8 48 0.3× 50 0.3× 18 0.5× 14 0.5× 27 1.0× 29 255

Countries citing papers authored by Michael J. Asmus

Since Specialization
Citations

This map shows the geographic impact of Michael J. Asmus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Asmus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Asmus more than expected).

Fields of papers citing papers by Michael J. Asmus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Asmus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Asmus. The network helps show where Michael J. Asmus may publish in the future.

Co-authorship network of co-authors of Michael J. Asmus

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Asmus. A scholar is included among the top collaborators of Michael J. Asmus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Asmus. Michael J. Asmus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tombs, Lee, Michael J. Asmus, I. Boucot, et al.. (2018). Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials. Drugs & Aging. 35(7). 637–647. 5 indexed citations
2.
Asmus, Michael J., et al.. (2014). Efficacy and tolerability of celecoxib in osteoarthritis patients who previously failed naproxen and ibuprofen: results from two trials. International Journal of Clinical Rheumatology. 9(6). 551–558. 3 indexed citations
3.
4.
Raskin, Philip, Cynthia Huffman, Cory Toth, et al.. (2013). Pregabalin in Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy. Clinical Journal of Pain. 30(5). 379–390. 30 indexed citations
5.
Asmus, Michael J., et al.. (2004). Methacholine Challenge Testing*. CHEST Journal. 125(2). 453–458. 25 indexed citations
6.
Hendeles, Leslie, Michael J. Asmus, & Sarah E. Chesrown. (2004). Evaluation of cytokine modulators for asthma. Paediatric Respiratory Reviews. 5. S107–S112. 17 indexed citations
7.
Asmus, Michael J., et al.. (2004). In Vitro Performance Characteristics of Valved Holding Chamber and Spacer Devices with a Fluticasone Metered‐Dose Inhaler. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(2). 159–166. 11 indexed citations
8.
Asmus, Michael J., et al.. (2003). Performance of a Corticosteroid Inhaler with a Spacer Fashioned from a Plastic Cold-Drink Bottle: Effects of Changing Bottle Volume. Journal of Asthma. 40(3). 237–242. 4 indexed citations
9.
Asmus, Michael J., et al.. (2003). In Vitro Performance of Two Common Valved Holding Chambers with a Chlorofluorocarbon‐Free Beclomethasone Metered‐Dose Inhaler. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(12). 1538–1544. 14 indexed citations
10.
Asmus, Michael J., et al.. (2002). In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers. Annals of Allergy Asthma & Immunology. 88(2). 204–208. 10 indexed citations
11.
Zar, Heather J., Michael J. Asmus, & Eugene Weinberg. (2002). A 500‐ml plastic bottle: An effective spacer for children with asthma. Pediatric Allergy and Immunology. 13(3). 217–222. 25 indexed citations
12.
Asmus, Michael J., et al.. (2002). Differences in Inhaled Fluticasone Bioavailability Between Holding Chambers in Children with Asthma. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 22(8). 947–953. 13 indexed citations
13.
Asmus, Michael J., B. A. Stewart, M. Teresi, et al.. (2002). Tobramycin as a Pharmacologic Tracer to Compare Airway Deposition from Nebulizers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 22(5). 557–563. 9 indexed citations
14.
Asmus, Michael J., Leigh M. Vaughan, Malcolm Hill, Sarah E. Chesrown, & Leslie Hendeles. (2002). Stability of Frozen Methacholine Solutions in Unit-Dose Syringes for Bronchoprovocation. CHEST Journal. 121(5). 1634–1637. 3 indexed citations
15.
Asmus, Michael J., et al.. (2001). Pulmonary function response to EDTA, an additive in nebulized bronchodilators. Journal of Allergy and Clinical Immunology. 107(1). 68–72. 24 indexed citations
16.
Asmus, Michael J., et al.. (2001). Multicenter Survey of Pharmacy Faculty and Student Metered-Dose Inhaler Knowledge. Journal of the American Pharmaceutical Association (1996). 41(3). 461–464. 2 indexed citations
17.
Asmus, Michael J., et al.. (2001). In Vitro Characteristics of Tobramycin Aerosol from Ultrasonic and Jet Nebulizers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(5). 534–539. 5 indexed citations
18.
Asmus, Michael J. & Leslie Hendeles. (2000). Levalbuterol Nebulizer Solution: Is It Worth Five Times the Cost of Albuterol?. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(2). 123–129. 32 indexed citations
19.
Asmus, Michael J., James M. Sherman, & Leslie Hendeles. (1999). Bronchoconstrictor additives in bronchodilator solutions. Journal of Allergy and Clinical Immunology. 104(2). S53–S60. 33 indexed citations
20.
Asmus, Michael J., et al.. (1997). Apparent decrease in population clearance of theophylline: Implications for dosage*. Clinical Pharmacology & Therapeutics. 62(5). 483–489. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas F. Morley Breakdown of academic impact, for papers by C. Maiolo Breakdown of academic impact, for papers by M.L. Diament Breakdown of academic impact, for papers by J.M. Daly Breakdown of academic impact, for papers by S. Lal Breakdown of academic impact, for papers by G.P. McLoughlin Breakdown of academic impact, for papers by E. S. Snell Breakdown of academic impact, for papers by David J. Cangemi Breakdown of academic impact, for papers by Kumar Ashutosh Breakdown of academic impact, for papers by Daniel M. Baer
Rankless by CCL
2026